Market Overview

Bernstein Weighs In On Vertex Move

Share:
Related VRTX
Short Sellers Come Back To Biotech Stocks
Short Sellers Retreat From Biotech Stocks

As shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have rallied over 40 percent following a press release concerning phase 3 studies of its Lumacaftor Ivacaftor combination regime, Bernstein analyst Geoffrey Porges issued a note with his take on the stock

Despite Tuesday's move, Porges maintained his Market Perform rating and $65 price target.

Porges noted the data are "clearly better than expected," but believes the immediate potential of the combination is substantially priced in. Moreover, he thinks short-covering will initially exaggerate the move.

Looking forward, Porges expects the regimen to receive FDA approval.

For a more detailed look into the press release, click here.

Latest Ratings for VRTX

DateFirmActionFromTo
Jan 2015Credit SuisseMaintainsBuy
Jan 2015CitigroupMaintainsBuy
Jan 2015BTIG ResearchInitiates Coverage onBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Bernstein Geoffrey PorgesAnalyst Color News Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→